KR20220065719A - 치료학적 효소 융합단백질의 파브리병에 기인하거나 동반되는 신장질환 예방 및 치료 용도 - Google Patents

치료학적 효소 융합단백질의 파브리병에 기인하거나 동반되는 신장질환 예방 및 치료 용도 Download PDF

Info

Publication number
KR20220065719A
KR20220065719A KR1020210156861A KR20210156861A KR20220065719A KR 20220065719 A KR20220065719 A KR 20220065719A KR 1020210156861 A KR1020210156861 A KR 1020210156861A KR 20210156861 A KR20210156861 A KR 20210156861A KR 20220065719 A KR20220065719 A KR 20220065719A
Authority
KR
South Korea
Prior art keywords
fusion protein
enzyme
pharmaceutical composition
region
immunoglobulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020210156861A
Other languages
English (en)
Korean (ko)
Inventor
최재혁
김진영
박초롱
김상윤
김정아
장두서
Original Assignee
한미약품 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 한미약품 주식회사 filed Critical 한미약품 주식회사
Publication of KR20220065719A publication Critical patent/KR20220065719A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6815—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01022—Alpha-galactosidase (3.2.1.22)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
KR1020210156861A 2020-11-13 2021-11-15 치료학적 효소 융합단백질의 파브리병에 기인하거나 동반되는 신장질환 예방 및 치료 용도 Pending KR20220065719A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20200152247 2020-11-13
KR1020200152247 2020-11-13

Publications (1)

Publication Number Publication Date
KR20220065719A true KR20220065719A (ko) 2022-05-20

Family

ID=81602509

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020210156861A Pending KR20220065719A (ko) 2020-11-13 2021-11-15 치료학적 효소 융합단백질의 파브리병에 기인하거나 동반되는 신장질환 예방 및 치료 용도

Country Status (12)

Country Link
US (1) US20230405093A1 (https=)
EP (1) EP4245311A4 (https=)
JP (1) JP2023549323A (https=)
KR (1) KR20220065719A (https=)
CN (1) CN116419760A (https=)
AU (1) AU2021378707A1 (https=)
CA (1) CA3196258A1 (https=)
CO (1) CO2023006437A2 (https=)
IL (1) IL302858A (https=)
MX (1) MX2023005580A (https=)
WO (1) WO2022103221A1 (https=)
ZA (1) ZA202304534B (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR133746A1 (es) * 2023-09-14 2025-10-29 Green Cross Corp NUEVA FORMULACIÓN LIOFILIZADA QUE CONTIENE PROTEÍNA DE FUSIÓN a-GALACTOSIDASA A

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
PT3345615T (pt) * 2010-03-01 2020-01-17 Bayer Healthcare Llc Anticorpos monoclonais otimizados contra inibidor da via do fator tecidual (tfpi)
WO2015009052A1 (ko) * 2013-07-16 2015-01-22 일동제약 주식회사 하이브리드 면역글로불린 fc와 효소의 융합단백질
AR107483A1 (es) * 2016-01-29 2018-05-02 Hanmi Pharm Ind Co Ltd Conjugado de enzimas terapéuticas
WO2018127920A1 (en) * 2017-01-05 2018-07-12 Protalix Ltd. Therapeutic regimen for the treatment of fabry using stabilized alpha-galactosidase
AU2018295994B2 (en) * 2017-07-07 2025-02-06 Hanmi Pharm. Co., Ltd. Novel therapeutic enzyme fusion protein and use thereof
FR3069340A1 (fr) * 2017-07-21 2019-01-25 Arkema France Procede de controle de l'orientation des nano-domaines d'un copolymere a blocs
CN111511910B (zh) * 2017-12-22 2024-11-08 韩美药品株式会社 具有新颖结构的治疗酶融合蛋白及其用途

Also Published As

Publication number Publication date
JP2023549323A (ja) 2023-11-24
CO2023006437A2 (es) 2023-06-09
US20230405093A1 (en) 2023-12-21
AU2021378707A1 (en) 2023-06-01
CA3196258A1 (en) 2022-05-19
EP4245311A4 (en) 2024-10-30
IL302858A (en) 2023-07-01
WO2022103221A1 (ko) 2022-05-19
CN116419760A (zh) 2023-07-11
MX2023005580A (es) 2023-05-29
ZA202304534B (en) 2024-10-30
EP4245311A1 (en) 2023-09-20
AU2021378707A9 (en) 2024-07-11

Similar Documents

Publication Publication Date Title
KR102712547B1 (ko) 신규한 구조를 갖는 치료학적 효소 융합단백질 및 이의 용도
US20220118049A1 (en) Methods for dosing an actriib antagonist and monitoring of treated patients
US20200255495A1 (en) Antagonists of actriib and uses for increasing red blood cell levels
AU2018200463B2 (en) ActRIIb antagonists and dosing and uses thereof
AU2016204287B2 (en) ActRIIB proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
RU2592670C2 (ru) Комбинированное применение ловушек gdf и активаторов рецепторов эритропоэтина для повышения содержания эритроцитов
AU2021201185A1 (en) Methods and compositions for treating ulcers
EP2303917A2 (en) Antagonists of actriib and uses for increasing red blood cell levels
TW200906849A (en) Natriuretic fusion proteins
KR20170088927A (ko) 골수형성이상 증후군 및 철적혈모구 빈혈을 치료하기 위한 방법
KR102569658B1 (ko) 컨쥬게이트 c1 에스테라제 억제제 및 그의 용도
US20240024426A1 (en) Hypotensive pharmaceutical composition comprising triple activator having activity for all of glucagon, glp-1, and gip receptors
KR20220065719A (ko) 치료학적 효소 융합단백질의 파브리병에 기인하거나 동반되는 신장질환 예방 및 치료 용도
KR20220065720A (ko) 치료학적 효소 융합단백질의 파브리병에 기인하거나 동반되는 신경병증 예방 및 치료 용도
US20250161211A1 (en) LIQUID FORMULATION COMPRISING A FUSION PROTEIN INCLUDING a-GALACTOSIDASE A
EA051281B1 (ru) Применение слитого с терапевтическим ферментом белка для предупреждения и лечения почечного заболевания, вызванного или связанного с болезнью фабри
EA051314B1 (ru) Применение слитого с терапевтическим ферментом белка для предупреждения и лечения нейропатии, считающейся следствием болезни фабри или ассоциированной с болезнью фабри

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 20211115

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20241112

Comment text: Request for Examination of Application